BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $27.31B, compared with -$30.74M a year earlier. Trailing-twelve-month net income was $27.6B. Over 3 fiscal years it compounded at +35.1% a year.
Context
- Net income amounted to 10.8% of revenue in FY2025, down 4.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 20 analysts of $592.26M (+69.8%) for the fiscal year ending Dec 2026, a step up from the -18.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $27.31B+60906.5% QoQ
- Last fiscal yearDec 2025
- $348.9M-18.3% YoY
- LTMSep 2026
- $27.6B+3808.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 348.9M USD
- Year-over-year change
- -18.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 348.9M | -18.3% |
| FY2024 | 2024-12-31 | 426.86M | +154.6% |
| FY2023 | 2023-12-31 | 167.65M | +18.4% |
| FY2022 | 2022-12-31 | 141.56M | +320.9% |
| FY2021 | 2021-12-31 | (64.08M) | — |
Net Income vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3808.4% is the highest of 11, against a peer median of +43.1%.
- Net income amounts to 2.7% of revenue for BMRN, versus a peer median of 45.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.6B USD | +3808.4% | +35.1% | 2.7% | |
| LTM Jun 2026 | $4.41B USD | +21.1% | +6.0% | 34.9% | |
| LTM Sep 2026 | €890.37M EUR | +482.2% | -27.9% | 73.7% | |
| LTM Jun 2026 | $875.31M USD | -15.4% | +38.4% | 76.9% | |
| LTM Jun 2026 | $807.99M USD | +353.2% | — | 16.8% | |
| LTM Jun 2026 | $695.45M USD | -11.4% | +14.4% | 97.5% | |
| LTM Mar 2026 | $608.92M USD | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $546.15M USD | +113.1% | +12.2% | 56.9% | |
| LTM Sep 2026 | $146.22M USD | +65.1% | -57.4% | 22.5% | |
| LTM Jun 2026 | $38.38M USD | -106.1% | — | 3.8% | |
| LTM Mar 2026 | $14.61M USD | +298.9% | -42.4% | 4.0% | |
| Peer median (excluding BMRN) | — | +43.1% | -0.4% | 45.9% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| Deferred Income Tax | (15.61M) | (52.09M) | (44.98M) | 56.1M | 48.74M |
| Stock-Based Compensation | 197.26M | 196.31M | 207.1M | 201.57M | 181.41M |
| Change in Working Capital | 66.03M | (96.38M) | (336.54M) | (216.4M) | (108.68M) |
| Accounts Receivables | 65.57M | (82.03M) | (190.44M) | (57.91M) | (228.05M) |
| Inventory | (35.06M) | (68.26M) | (157.06M) | (63.53M) | 119.21M |
| Accounts Payables | 15.69M | 59.02M | 68.85M | (32.24M) | 66.14M |
| Other Working Capital | 19.83M | (5.1M) | (57.9M) | (62.72M) | (65.97M) |
| Other Non-Cash Items | 12.89M | (115.47M) | 61.65M | 8.29M | 278.07M |
| Operating Cash Flow | 304.54M | 175.9M | 159.26M | 572.84M | 827.99M |
| Capital Expenditures | (119.23M) | (120.96M) | (107.61M) | (97.42M) | (103.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (285.19M) |
| Purchases of Investments | (937.14M) | (611.81M) | (868.5M) | (410.25M) | (355.88M) |
| Sales of Investments | 691.05M | 620M | 864.86M | 633.02M | 337.8M |
| Other Investing Activities | (24.64M) | 103.33M | (10.92M) | (853K) | (7.94M) |
| Investing Cash Flow | (366.31M) | (20.03M) | (111.24M) | 136.49M | (414.24M) |
| Debt Repayment | (3.04M) | (2.61M) | (2.29M) | (494.99M) | 0 |
| Common Stock Issued | 0 | 69.33M | 69.35M | 0 | 14.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.99M | (85.38M) | (85.79M) | (31.46M) | (56.85M) |
| Financing Cash Flow | (48K) | (18.65M) | (18.73M) | (526.45M) | (42.39M) |
| Effect of Forex Changes | (57K) | 32K | 1.31M | 4.83M | (2.52M) |
| Net Change in Cash | (61.88M) | 137.26M | 30.6M | 187.72M | 368.84M |
| Free Cash Flow | 185.31M | 54.94M | 51.65M | 475.42M | 724.96M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.